UK markets open in 3 hours 32 minutes
NIKKEI 225
39,155.16 +117.00 (+0.30%) HANG SENG
18,071.73 -295.22 (-1.61%) CRUDE OIL
77.62 -0.12 (-0.15%) GOLD FUTURES
2,320.60 -6.40 (-0.28%) DOW
38,868.04 +69.05 (+0.18%) Bitcoin GBP
53,533.20 -1,230.15 (-2.25%)
Mosaic ImmunoEngineering, Inc. (CPMV)
OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
At close: 03:00PM EDT
| Previous close | 0.2200 |
| Open | 0.3200 |
| Bid | 0.1030 x 0 |
| Ask | 0.5500 x 0 |
| Day's range | 0.2200 - 0.3200 |
| 52-week range | 0.1020 - 1.0000 |
| Volume | |
| Avg. volume | 569 |
| Market cap | 1.593M |
| Beta (5Y monthly) | -1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Mar 2007 |
| 1y target est | N/A |
- GlobeNewswire
Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
AGOURA HILLS, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that it has entered into a binding term-sheet with Mosaic ImmunoEngineering, Inc. (OTCPK: CPMV) (“Mosaic”) under which Mosaic will acquire rights to Oncotelic’s clinical-stage necroptosis cancer therapies. Oncotelic’s necroptosis therapeutics work by disrupting tumor blood flow resulting in immunogenic tumor cell death through “death re
© 2024 Yahoo. All rights reserved.